This is an IgM antibody that can be given as a nasal spray that may have prophylactic and treatment uses if given soon before or after exposure. It's intended use is *very* different to a vaccine and the comparison does not seem especially useful.
The 230-fold potency figure is comparing the IgM antibody against an IgG antibody on which it was based. Clearly this is a useful boost but no comparison was made against a vaccine.
It was tested as a single dose given either 6 hours before or after infection in mice. It is not clear how frequently it would need to be administered in humans to provide continuous protection - but this would not be it's likely use. A single dose would provide only temporary protection. It might have value as a treatment after a COVID diagnosis is made or as a prophylactic if you have been exposed to someone with COVID.